Sacituzumab govitecan (IMMU-132) (CAS: 1491917-83-9)
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) designed for targeted cancer therapy. It combines a monoclonal antibody that binds to Trop-2, a protein overexpressed in many cancers, with SN-38, the active metabolite of irinotecan, a topoisomerase I inhibitor.
Key Features:
- Targeted Therapy: The antibody targets Trop-2 on cancer cells, delivering the cytotoxic agent directly to the tumor.
- Cytotoxic Payload: SN-38 inhibits topoisomerase I, causing DNA damage and cancer cell death.
- Enhanced Efficacy: This ADC delivers higher concentrations of the cytotoxic agent to tumors, improving effectiveness and reducing systemic side effects.
Applications:
- Metastatic Triple-Negative Breast Cancer (mTNBC): Approved for patients who have received at least two prior therapies for metastatic disease.
- Metastatic Urothelial Cancer (mUC): Approved for patients who have previously received platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.
- Hormone Receptor-Positive, HER2-Negative Breast Cancer: Approved for patients who have received endocrine therapy and at least two other treatments for metastatic disease.
Handling and Storage:
- Storage: Store at -20°C, protected from light and moisture.
- Handling: Use standard laboratory precautions when handling this reagent.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.